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OBJECTIVES: Compliance with antihypertensives is inﬂuenced
by various factors, and inﬂuences blood pressure (BP) control
and cardiovascular outcomes. Differences in compliance, eg. the
improvement associated with ﬁxed-dose combinations (FDCs),
are acknowledged, but have not been incorporated into cost-
effectiveness modeling because the chain of causality between
compliance and outcomes is complex. We developed a method to
quantify this chain of effects which can use simple compliance
parameters such as medication possession ratios, or more sophis-
ticated inputs; it can also be tailored to speciﬁc decision prob-
lems. METHODS: First the effect of variation in compliance on
simulated dosing histories is modeled. Second, the rate of fall/
rise in BP on initiating/withdrawing treatment, and the full-
compliance BP reduction, are used to estimate corresponding BP
trajectories. Finally clinical endpoints are modeled from these
BP trajectories, based on existing evidence. In an illustrative
example, the effect of choosing an FDC over the corresponding
component-based regime was modeled. The FDC effect was
modeled as an 11% reduction in missed doses [reference], dis-
tributed evenly across interruptions of different lengths. Systolic
blood pressure (SBP) trajectories were estimated assuming bio-
equivalence between FDC and component-based regimes, and
the mean SBP calculated. The Framingham risk equation was
used to predict the number of strokes which would be expected
on the component-based regime, and the expected number which
FDC use would avoid through superior compliance. RESULTS:
This approach allows quantiﬁcation of compliance-mediated
health effects with great ﬂexibility. CONCLUSIONS: More
detailed data on the effects of FDC use on compliance can be
incorporated, and different treatment efﬁcacies and/or different
durations of action can be substituted, as can different BP
summary statistics, different clinical endpoints, and different
sources for the relationships between them. Reference: Taylor A
and Shoheiber O. Adherence to antihypertensive therapy with
ﬁxed-dose amplodipine besylate/benazepril versus comparable
component-based therapy. Congestive Heart Failure 2003;9:
324–32.
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OBJECTIVES: To develop an epidemiological and economic
model of cardiovascular disease (CVD, comprising coronary
heart disease and stroke) that can be used to predict the future
incidence of CVD in a given population (with representative
cross-sectional data on cardiovascular risk factors) and under-
take cost-effectiveness analyses of primary preventive strategies.
METHODS: The CPM is a Markov model comprising four
health states: ‘Alive without CVD’, ‘Alive with CVD’, ‘Dead
from CVD’ and ‘Dead from non-CVD causes’. Individual sub-
jects’ risks of CVD are derived from Framingham and UKPDS
risk equations for non-diabetic and diabetic individuals, respec-
tively. The risks of non-CVD death are drawn from local mor-
tality data. To illustrate the function of the CPM, it was
populated with 1335 Australian subjects from the nationally-
representative 1999–2000 Australian Diabetes, Obesity and
Lifestyle study who were: aged 35–74 years; free of CVD; and
met current criteria for reimbursed access to statin treatment.
Follow-up was simulated until death or age 75 years. The cost-
effectiveness of atorvastatin for the primary prevention of CVD
was modelled via decision analysis, using efﬁcacy data from a
recent meta-analysis of randomized trials and Australian cost
and utility data. A 5% annual discount rate was applied.
RESULTS: The CPM predicted that of Australians currently
aged 35–74 years who were CVD-free but met criteria for
lipid-lowering treatment, 23.3% would develop CVD and
24.3% would be dead by age 75 years without statin treatment.
Atorvastatin would reduce these ﬁgures to 16.5% and 22.2%,
representing numbers needed to treat of 14.7 and 46.2 to prevent
CVD and death, respectively. The estimated ICERs were
AUD$54,100/YoLS and AUD$35,600/QALY. CONCLUSIONS:
The CPM allows for the prediction of future incidences of CVD
in a population where representative cross-sectional data on
cardiovascular risk factors are available. It can also be applied to
cost-effectiveness analyses of primary preventive interventions
for that population.
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OBJECTIVES: To assess the strength and duration of pelvic
ﬂoor muscle contraction and the ability of muscle relaxation
before and during pregnancy. METHODS: Our study focused
on examining the strength of duration and ability of relaxation
of pelvic ﬂoor muscle in cases of nulliparous young women and
pregnant women in the second and third trimesters. The mea-
surement of parameters characterizing the functional abilities
of the muscle was performed by vaginal pressure measurement
equipment. The statistical data were calculated according to
mean, standard deviation, Fisher’s exact test, T-test methods
and the results were considered to be relevant at p < 0.05.
RESULTS: Out of 119 measurements the data of 93 women
were processed. The maximum muscle strength (103.13
H2Ocm  54.12) of nulliparous women (n = 36) was signiﬁ-
cantly higher (p = 0.00348) than that of pregnant women
(n = 57); (68.3 H2Ocm  47.23). The duration of maximum
contraction in case of nulliparous women (6.4 sec  4.9)
proved to be markedly longer (p = 0.011067) than during preg-
nancy (3.98 sec  4.011). Although the maximum muscle
strength is higher in the second trimester than in the third tri-
mester the difference is not signiﬁcant. Regarding the duration
of maximum contraction no marked difference was found. A
total ability of relaxation could only be observed in one third of
the sample but no signiﬁcant difference was detected between
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